Gross GJ, Nithipatikom K (2009)
Soluble epoxide hydrolase: a new target for cardioprotection
Curr Opin Investig Drugs 10: 253

Parrish AR, Chen G, Burghardt RC, Watanabe T, Morisseau C, Hammock BD (2009)
Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase
Cell Biol Toxicol 25: 217

Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM (2008)
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo
American Journal of Physiology Heart Circ Physiol 295: H2128

Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD (2007)
Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase
Bioorganic & Medicinal Chemistry 15: 312

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ (2007)
Soluble epoxide hydrolase: a novel therapeutic target in stroke
Journal of Cerebral Blood Flow & Metabolism 27: 1931

Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD (2006)
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors
Proc Natl Acad Sci U S A 103: 13646

Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD (2005)
Soluble epoxide hydrolase is a therapeutic target for acute inflammation
Proc Natl Acad Sci U S A 102: 9772

Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD (2002)
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases
Biochemical Pharmacology 63: 1599

Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD (1999)
Potent urea and carbamate inhibitors of soluble epoxide hydrolases
Proc Natl Acad Sci U S A 96: 8849